Trials / Completed
CompletedNCT05524103
Study to Evaluate the Safety and Pharmacokinetics of ALMB-0166 in Patients With Acute Spinal Cord Injury
A Phase Ⅰ, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ALMB-0166 in Patients With Acute Spinal Cord Injury
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- AlaMab Therapeutics (Shanghai) Inc. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the safety, tolerability and pharmacokinetics of ALMB-0166 in patients with acute spinal cord injury.
Detailed description
This is a phase 1, randomized, double-blinded, placebo-controlled, single ascending dose study to evaluate the safety, tolerability and pharmacokinetics of ALMB-0166 in patients with acute spinal cord injury.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ALMB-0166 | A single dose of ALMB-0166 injection. |
Timeline
- Start date
- 2022-04-15
- Primary completion
- 2025-02-08
- Completion
- 2025-02-08
- First posted
- 2022-09-01
- Last updated
- 2025-11-18
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT05524103. Inclusion in this directory is not an endorsement.